Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Takotsubo Registry

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Nuoroda įrašoma į mainų sritį
StatusasVerbavimas
Rėmėjai
Cedars-Sinai Medical Center

Raktažodžiai

Santrauka

The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria of Takotsubo Registry protocol. Subjects will also be invited to provide a blood sample utilizing a Mitra kit sent to their homes. Researchers from the Barbra Streisand Women's Heart Center will analyze Registry data to identify Takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted Takotsubo treatments.

apibūdinimas

Registry outreach will begin with an informational and inspirational website and will utilize social media and patient-driven activism through Facebook, blogs and Twitter modalities that have demonstrated efficiencies in other patient-centered research efforts. Subjects will upload specific clinical materials into Cedar-Sinai's web-enabled cloud storage and which will be screened by trained Smidt Heart Institute physicians. The Registry utilizes on-line, e-consent and enrollment connected to a REDCap database that will allow efficient data input for analysis. All potential subjects who have been diagnosed with Takotsubo or have been informed by their physician that they meet diagnosis criteria, will need to provide information for review that includes: hospitalization records, from the time of Takotsubo event, with laboratory data (particularly -- troponin level), ECG and CTA. Registrants will be asked to respond to annual update surveys.

The goal is to accurately understand the prevalence, recurrence and prospective status of the Takotsubo, to determine which individuals are at risk of reoccurrence or subsequent adverse event and to determine potential treatment targets to develop therapeutic strategies

Primary:

- To establish a large USA-based database for patients with Takotsubo with a convenient and easy to use on-line patient-advocate registry using digital media marketing, Box cloud data access and storage, accurate case adjudication, and automated follow-up.

- Participants will also be offered the option of participating in the Takotsubo Proteomic Registry by providing remote ambulatory Mitra blood samples.

Secondary:

• To establish a clinical trial platform for patient-centered point-of-care trials to improve diagnostics, clinical care and outcomes.

Datos

Paskutinį kartą patikrinta: 03/31/2019
Pirmasis pateikimas: 03/05/2019
Numatytas registravimas pateiktas: 04/07/2019
Pirmas paskelbtas: 04/09/2019
Paskutinis atnaujinimas pateiktas: 04/28/2019
Paskutinis atnaujinimas paskelbtas: 04/30/2019
Faktinė studijų pradžios data: 01/31/2019
Numatoma pirminio užbaigimo data: 01/31/2029
Numatoma studijų užbaigimo data: 01/31/2029

Būklė ar liga

Takotsubo Cardiomyopathy

Fazė

-

Tinkamumo kriterijai

Amžius, tinkami studijuoti 18 Years Į 18 Years
Tinkamos studijoms lytysAll
Mėginių ėmimo metodasProbability Sample
Priima sveikus savanoriusNe
Kriterijai

Inclusion Criteria:

- Have received a diagnosis of Takotsubo from their physician and consent to enroll

- Submit full medical records needed for Takotsubo adjudication

Exclusion Criteria:

- Younger than 18 years

- Unable to provide informed consent

- Unable to provide the necessary documentation needed for screening purposes

Rezultatas

Pirminės rezultatų priemonės

1. Number of participants with Prevalence of the Takotsubo [Baseline, Annual follow-up up to 30years]

Prevalence of the Takotsubo will be measured annually. Change from baseline will be assessed.

2. Number of participants with Recurrence the Takotsubo [Baseline, Annual follow-up up to 30years]

Recurrence the Takotsubo will be measured annually. Change from baseline will be assessed.

3. Annual update surveys will collect data on patient's prospective health status following Takotsubo event [Baseline, Annual follow-up up to 30years]

Prospective statusof the Takotsubo will be measured annually. Change from baseline will be assessed.

4. Risk factors affecting which patients, having had one Takotsubo event, will more likely experience a Takotsubo reoccurrence or related subsequent adverse event [Baseline, Annual follow-up up to 30years]

Risk factors for reoccurrence or subsequent adverse event will be collected annually.

Prisijunkite prie mūsų
„Facebook“ puslapio

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

  • Dirba 55 kalbomis
  • Žolelių gydymas, paremtas mokslu
  • Vaistažolių atpažinimas pagal vaizdą
  • Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
  • Skaitykite mokslines publikacijas, susijusias su jūsų paieška
  • Ieškokite vaistinių žolelių pagal jų poveikį
  • Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais

Google Play badgeApp Store badge